Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
• Jazz Pharmaceuticals stock is showing positive momentum. What’s ahead for JAZZ stock?
This partnership includes $56 million in upfront payments and potential milestone payments totaling up to $792 million, which could significantly enhance Jazz’s oncology portfolio as it focuses on gastrointestinal cancers.
What It Means For JAZZ
The collaboration with AbCellera aims to leverage its antibody discovery engine for developing treatments targeting multiple solid tumors.
In addition, Jazz and AbCellera may mutually agree to initiate up to two additional programs, and to have AbCellera conduct certain activities for investigational new drug-enabling studies and manufacture clinical supply for any program under the collaboration.
The strategic move aligns with the Ireland-domiciled biopharmaceutical’s commitment to expanding its oncology capabilities and could lead to innovative therapies for patients with limited options.
Recent Zepzelca Phase 3 Trial Miss
Last week, Jazz Pharmaceuticals shared topline results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer.
The trial did not meet its primary endpoint of overall survival, evaluating Zepzelca as monotherapy or in combination with irinotecan compared to the investigators’ choice of topotecan or irinotecan.
JAZZ Technical Outlook: Key Levels and Momentum
With Jazz Pharmaceuticals trading at $230, the stock is positioned 1.8% below its 20-day simple moving average (SMA) of $234.30.
The stock is performing well relative to its longer-term averages, sitting 5% above the 50-day SMA and 16% above the 100-day SMA, indicating a bullish trend in the medium to long term.
The primary momentum indicator, the Relative Strength Index (RSI), is currently at 48.58, suggesting a neutral momentum phase.
This indicates that the stock is neither overbought nor oversold, allowing for potential upward movement if positive sentiment continues.
Key Resistance: $242— Nearby level where rebounds can stall, aligning with previous price action and psychological resistance.
Key Support: $224 — Level where buyers previously stepped in, providing a safety net for the stock.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an consensus price target of $231.73. Recent analyst moves include:
- BofA Securities: Buy (Raises target to $307 on June 10)
- Barclays: Overweight (Raises target to $253 on May 27)
- Bernstein: Initiated with Market Perform (Target $229 on May 22)
How JAZZ Ranks On Benzinga Edge Momentum
Below is the Benzinga Edge scorecard for Jazz Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 91.92) — Stock is outperforming the broader market.
The Verdict: Jazz Pharmaceuticals’ Benzinga Edge signal reveals a momentum-driven story, indicating strong performance relative to the market. The company’s recent strategic moves and solid analyst outlook suggest a positive trajectory ahead.
ABCL/JAZZ Stock Price Actions: Jazz Pharmaceuticals shares were up 0.70% at $228.46, and ABCL stock was up 10.71% at $5.54 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo Courtesy: Shutterstock.com
Recent Comments